Venus Chemicals And Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 11 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 26.74 Cr
as on 03-07-2024
- Satisfied Charges ₹ 4.10 Cr
as on 03-07-2024
- Revenue -59.00%
(FY 2023)
- Profit -70.33%
(FY 2023)
- Ebitda -45.13%
(FY 2023)
- Net Worth 12.41%
(FY 2023)
- Total Assets 34.35%
(FY 2023)
About Venus Chemicals And Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹26.74 Cr. The company has closed loans amounting to ₹4.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Indira Madderla, Sainath Madderla, and Madderla Shankar serve as directors at the Company.
- CIN/LLPIN
U24100TG2013PTC085597
- Company No.
085597
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Feb 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Kapra, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Venus Chemicals And Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Indira Madderla  | Director | 05-Feb-2013 | Current |
| Sainath Madderla | Additional Director | 26-Feb-2018 | Current |
| Madderla Shankar | Director | 05-Feb-2013 | Current |
Financial Performance of Venus Chemicals And Drugs.
Venus Chemicals And Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 59% decrease. The company also saw a substantial fall in profitability, with a 70.33% decrease in profit. The company's net worth Soared by an impressive increase of 12.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Venus Chemicals And Drugs?
In 2023, Venus Chemicals And Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 28 Jul 2023 | ₹26.74 Cr | Open |
Others Creation Date: 11 Nov 2021 | ₹3.00 Cr | Satisfied |
Indian Overseas Bank Creation Date: 04 Feb 2015 | ₹1.10 Cr | Satisfied |
How Many Employees Work at Venus Chemicals And Drugs?
Venus Chemicals And Drugs has a workforce of 20 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Venus Chemicals And Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Venus Chemicals And Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
